Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2015 Mar;16(3):247-9.
doi: 10.1016/S1470-2045(15)70071-9. Epub 2015 Feb 18.

Moving the goal posts in prostate cancer trials

Ravi A Madan  1 , James L Gulley  2
Affiliations
Comment

Moving the goal posts in prostate cancer trials

Ravi A Madan et al. Lancet Oncol. 2015 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare that we have no competing interests.

Comment on

References

    1. Saad F, Fizazi K, Jinga V, et al., for the ELM-PC 4 investigators. Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial. Lancet Oncol 2015; published online Feb 18. 10.1016/S1470-2045(15)70027-6. - DOI - PubMed
    1. Fizazi K, Jones R, Oudard S, et al. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. J Clin Oncol 2015; 10.1200/JCO.2014.56.5119. - DOI - PMC - PubMed
    1. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014; 32: 3436–48. - PMC - PubMed
    1. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371: 1028–38. - PMC - PubMed
    1. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33. - PMC - PubMed

MeSH terms